Liver Cancer | Tumor

MET Inhibitor May Be Effective in Treating Patients With Hepatocellular Carcinoma With MET Overexpression Who Were Not Successful With Nexavar

April 13th 2021, 3:00pm


A 500 mg dose of Tepmetko, a MET inhibitor, in patients with hepatocellular carcinoma who were previously treated with Nexavar led to a 12-week progression-free survival rate of 63.3%.

Raising Awareness Around Liver Cancer and Disease

April 9th 2021, 6:00pm


CURE spoke with Dr. Marty T. Sellers and Dr. Laura M. Kulik, on behalf of the Blue Faery, about liver cancer and disease – its treatments, causes and areas outside of therapy.

FDA Approves Radiation Therapy for Outpatient Setting in Liver Cancer Subtype

March 19th 2021, 9:00pm


Patients with this liver cancer subtype do not need to be hospitalized to receive this treatment and, according to the agent’s manufacturer, Boston Scientific, can typically receive the therapy in approximately an hour during an outpatient procedure.

Genomic Testing Offers New Therapy Options for Hepatobiliary Cancers

March 17th 2021, 6:00pm


Genomic testing has allowed patients to receive more specific drugs that target mutations in their tumors.

Adjuvant Radiotherapy Shows Survival Benefit for Patients Who Had Resection for Distal Cholangiocarcinoma

February 25th 2021, 10:00pm


Following resection with radiotherapy increased survival rates for patients compared with those who did not receive the additional treatment.

Cholangiocarcinoma: Understanding Potential Paths For Treatment

January 27th 2021, 7:00pm


There are multiple treatment patients for patients with cholangiocarcinoma, here's what you need to know about them.

Aliqopa With Chemotherapy Did Not Improve Short-Term Progression-Free Survival

January 27th 2021, 7:00pm


In a phase 2 study of 24 patients with biliary cancer, Aliqopa in combination with Gemzar and chemotherapy led to a six-month progression-free survival rate of 51% with a median overall survival of 13.7 months.

Novel Therapy Shows Promise in Liver Cancer Subset, May Address ‘Urgent Need for New Therapies’

January 21st 2021, 7:00pm


“Along with a tolerable safety profile and supportive quality of life, these final efficacy results demonstrate the clinical benefit of (Tibsovo) in (previously treated patients with IDH1-mutant cholangiocarcinoma), for which there is an urgent need for new therapies,” said an expert from Massachusetts General Hospital, who presented the data.

Tecentriq-Avastin Combo Continues to Show Improved Survival Benefit in Patients with Advanced Liver Cancer

January 19th 2021, 7:00pm


“This is the longest survival seen in a phase 3 study of advanced liver cancer,” lead study author Dr. Richard S. Finn, of the UCLA Jonsson Comprehensive Cancer Center, said in a virtual presentation of the data.

Living in Low-Income, Rural Households Associated With Greater Risk of Death for Patients With Liver Cancer

January 14th 2021, 10:30pm


Patients with hepatocellular carcinoma who live in low-income and rural households are less likely to receive high quality care and therefore are more likely to be diagnosed with an advanced stage cancer.